CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”)

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement